JNCCN 360 – Non–Small Cell Lung Cancer – (NEW Update) Nivolumab in NSCLC
Posted: Thursday, April 4, 2024 The U.S. Food and Drug Administration (FDA) first approved nivolumab (Opdivo) to treat metastatic squamous non–small cell lung cancer (NSCLC) in 2015. Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody against PD-1. This made it the first immunotherapy to be approved for the treatment of any type of lung cancer, and it brought about a paradigm shift in the management of advanced NSCLC. It has not only significantly improved the prognosis of patients